Psilocybin-assisted therapy for depression is now legally accessible in ten additional states as regulatory frameworks mature.
Clinical outcomes data continue to support the treatment for patients who have failed traditional antidepressants.
Insurance coverage remains limited but is expanding through pilot programs.
